Merck’s pembrolizumab, sold as Keytruda, showed promising signs of efficacy in a particularly deadly brand of breast cancer, early data that could expand the use for a new class of treatments expected to take the market by storm.

…read more

Source: Merck shows PD-1’s promise in breast cancer with positive early results


0 No comments